The Prolongation of the Action of Pharmaceutical Preparations by Mixing or Combining Them With Polymers

Abstract

Elxtron and L-n) difhction parrems uers [&en from four different N I , -~R~ alloys. uith x = 0 25.0.35.0 ?J and 0 SO. to Lnaehma thc cxtslcnw and shape of the diffuru tntens~ty. which gwes us mformamn about rtructurd Ruciu3iions A p ? d w rhapc of dlHuse scxtenq has o c m obsmcd at I O 0 md I IO ma their cquirdent posmons in the pmncms. thc shap of the uiffusr. mtcnsir> at [he IO0 position chvlgins sith PI content In the all0)s. The shape of the diffue mehit) at the 100 position ior th: I = 0 25 allo) IS rod.lAe. but thc shape 1s ncxly sphmcil for the I = 0 50 dlo) Thi \.raj diffuse scetenng intensities urn mezurcd from the I = 0.50 s m z l c -q s d allo) at room tempmure. m d the Wmen-Coulq shon-rmgc order p x m e t e n neIe determned aft<, mi.),mg thr. dan Thc corrc.mon length has been deduced to be aboJt 19 A from <,ttmang the i n r e r~e of In< full width at hall-mumum of the diffuse peak

Biological applications of functionalised polymers—a review

“…[25][26][27][28][29][30][31][32] Because macromolecules diffuse slowly in solution and penetrate cell membranes very slowly, coupling of a biologically active molecule to polymeric material is one of several approaches used to enhance the specificity and duration of drug activity. The therapeutic activity of such polymeric drugs may be caused by either the macromolecular nature of the polymer-drug compound itself, where the drug-polymer linkage is not attacked, or it may be caused by the liberation of the drug molecule though gradual destruction of the drug-polymer link, the polymer being used only as the carrier for the normal pharmaceutical agent.…”

Preparation of new polymer from podophyllotoxin derivative

“…For decreasing toxic effects, it is a suitable way that the C 4 -OH of PPT was substituted by suit group such as etoposide [4,5] and teniposid [6,7], which have been used as a new antitumor agent. A potentially significant aspect of the use of a polymeric drug is the question of a depot effect which might be brought about by either reduced absorption or reduced excretion of the drug [8]. More important is the possibility of varying drastically the pharmacodynamics of drug systems by the use of polymeric substrates.…”

Structure and properties of pharmacologically active polymers

“…Drug combination along the polymer chain. A potentially significant aspect of the use of a polymeric drug which has been discussed even in the older review literature [3] is the question of a depot effect which might be brought about by either reduced absorption or reduced excretion of the drug. More important is the possibility of varying drastically the pharmacodynamics of drug systems by the use of polymeric substrates.…”